Revisiting long-held tenets in GPCR and G protein signal transduction with macrocyclic inhibitors of heterotrimeric Gq/11 proteins and state-of-the-art genome editing
Revisiting long-held tenets in GPCR and G protein signal transduction with macrocyclic inhibitors of heterotrimeric Gq/11 proteins and state-of-the-art genome editing
批准号:
290847012
负责人:
Professorin Dr. Evi Kostenis
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Units
财政年份:
2016
资助国家:
德国
项目状态:
已结题
起止时间:
2015-12-31 至 2022-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
G protein-coupled receptors and their associated G proteins are involved, directly or indirectly, in virtually every physiological process in the human body. Despite the discovery of G proteins about 25 years ago and their relevance for responding and maintaining homeostasis in relation to numerous extracellular cues, selective inhibition of this protein family with cell-permeable inhibitors remains a fundamental challenge. We recently contributed two significant advances to this field: (1) identification of a novel molecular mechanism to specifically interfere with G protein function: GTP-entry inhibitors. These are molecules that interdict G protein signaling by trapping Galpha in the empty pocket conformation. (2) in-depth investigations into selectivity and mode of action of the plant-derived depsipeptide FR900359. We found that FR is exceptionally selective for inhibition of Gq-mediated signal transduction involving Galphaq, Galpha11, and Galpha14 proteins, but absolutely inert on all other mammalian Galpha isoforms. Given its outstanding value as molecular probe to specifically interdict Gq signaling via inhibition of GDP release, we now want to take advantage of FR to (i) investigate the general capacity of GPCRs to signal in the absence of activated G proteins, (ii) probe the structural and molecular basis for its mode of action and exquisite selectivity for inhibition of Gq family proteins, (iii) apply the knowledge from (ii) to foster design of novel inhibitors targeting those Galpha subunits for which selective inhibitors are still lacking. Moreover, we intend to apply and extend a broad range of biological, pharmacological and biochemical assays for 'mechanistic fingerprinting' of novel inhibitors synthesized within our consortium. With existing and newly developed Galpha tools we expect to significantly advance and refine our understanding of basic principles utilized by cells to perceive external stimuli and translate these into specific instructions to modulate cell function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Coordination Funds
-
批准号:290847320
-
项目类别:Research Units
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Professorin Dr. Evi Kostenis
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于Relm-β核转位激活EndMT促进肺动脉高压研究肺心汤预防 Long COVID 机制
-
批准号:2025JJ90008
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:刘慧
-
依托单位:
维生素D调控巨噬细胞极化在改善“Long COVID”中作用和机制的分子流行病学研究
-
批准号:82373643
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:马翔宇
-
依托单位:
long non-coding RNA(lncRNA)-activatedby TGF-β(lncRNA-ATB)通过成纤维细胞影响糖尿病创面愈合的机制研究
-
批准号:LQ23H150003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:厉怡
-
依托单位:
Long-TSLP和Short-TSLP佐剂对新冠重组蛋白疫苗免疫应答的影响与作用机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:叶亮
-
依托单位:
水稻LONG PANICLE1基因调控穗长的分子机制研究
-
批准号:32101768
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:刘二宝
-
依托单位:
METTL3通过调控LncHOTAIRM1激活CD8+T细胞自噬介导肝移植急性排斥反应
-
批准号:82070673
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:汪根树
-
依托单位:
long-TSLP诱导的M2型巨噬细胞调控肺成纤维细胞线粒体融合在哮喘气道重塑中的作用和机制
-
批准号:81970032
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:蔡绍曦
-
依托单位:
不同远距离基因互作对胚胎干细胞中Sox2基因调控的研究
-
批准号:31970592
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张玉波
-
依托单位:
转座因子调控多能干细胞染色质三维结构中的作用
-
批准号:31970589
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2019
-
负责人:ANDREW P·HUTCHINS
-
依托单位:
LONG8及其互作蛋白LGIP1调控水稻籽粒大小的分子机理研究
-
批准号:31871219
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:李娜
-
依托单位: